Personalising Treatment Decisions| Oncotype DX® Tests | Oncotype IQ® International

Exact Sciences brings the promise of precision medicine to life with Oncotype IQ, a full suite of genomic tests.

GUIDELINES UPDATE

NCCN Breast Cancer Guidelines

New NCCN Breast Cancer Guidelines recognize Oncotype DX Breast Recurrence Score^® as the “preferred” and only multigene test to predict chemotherapy benefit in node-positive early-stage breast cancer

Landmark RxPONDER Trial Results

Presented at the 2020 SABCS

New data clarifies the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Recurrence Score^® results of 0 to 25

Exact Sciences' Response to COVID-19

A Letter from our CEO, Kevin Conroy

"Cancer doesn’t stop and neither will we. Our team’s commitment to serving patients is unwavering, and we’ll continue working hard to do just that."

READ THE LETTER

Deborah, an Oncotype DX patient

NCCN Breast Cancer Guidelines

New NCCN Breast Cancer Guidelines recognize Oncotype DX Breast Recurrence Score^® as the “preferred” and only multigene test to predict chemotherapy benefit in node-positive early-stage breast cancer

Landmark RxPONDER Trial Results

Presented at the 2020 SABCS

New data clarifies the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Recurrence Score^® results of 0 to 25

Exact Sciences' Response to COVID-19

A Letter from our CEO, Kevin Conroy

"Cancer doesn’t stop and neither will we. Our team’s commitment to serving patients is unwavering, and we’ll continue working hard to do just that."

READ THE LETTER

Oncotype IQ Portfolio of Tests

Breast Cancer

Prostate Cancer

Colon Cancer

Oncotype IQ Portfolio of Tests

The only multigene expression genomic test commercially available proven to predict a patient’s individual benefit from chemotherapy.

Decide whether immediate treatment is necessary or confidently opt for active surveillance. For more information, please visit our U.S. website.

The first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease. For more information, please visit our U.S. website.

The first clinically validated genomic test to quantify the risk of local recurrence (DCIS or invasive) in ductal carcinoma in situ. For more information, please visit our U.S. website.

Improving Patient Outcomes

What Is the Test

The Oncotype DX test reveals the underlying tumour biology to help guide treatment decisions.

Prognostic vs. Predictive

Only a truly predictive test can identify the right treatment for the right patient.

LEARN WHY IT MATTERS

Latest TAILORx Data

The landmark TAILORx results provide definitive answers on which early stage ER+, HER2-, N0 breast cancer patients can benefit from chemotherapy.

Contact Us

Terms & Conditions

Worldwide Websites

Terms & Conditions

Worldwide Websites

Copyright © 2004- Genomic Health, Inc. All Rights Reserved.

In the US and certain other jurisdictions, Genomic Health, Oncotype DX, Oncotype IQ, Recurrence Score, Oncotype DX Breast Recurrence Score, Oncotype DX Colon Recurrence Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are registered trademarks, and "Making cancer care smarter" and GPS are pending registered trademarks, of Genomic Health, Inc.

Making cancer care smarter.™



X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.